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Background: Chronic comorbidities and some of the commonly-used medications are thought to affect cancer
patients’ outcomes, but their relative impact on esophageal carcinoma (EC) has not been well studied. The purpose
of the study was to identify the chronic comorbidities and/or commonly-used medications that impact EC patient
survival.
Methods: A total of 1174 EC patients treated with chemoradiotherapy (CRT) with or without surgery in one
institution from 1998 to 2012 were retrospectively included. Seven kinds of frequently occurring chronic
comorbidities and 18 types of regularly-taken medications were obtained from medical records. Since it is expected
prognostic factors have different effects between surgery patients and non-surgery patients, the impact value of all
variables and the corresponding interactions with surgery on survival were evaluated in Cox proportional hazards
regression model. Overall mortality, EC-specific mortality and non EC-specific mortality were endpoints.
Results: We found that atrial fibrillation was the only comorbidity that showed a significant impact on non-EC
specific survival for all patients (HR 1.72, P = 0.03), whereas hypothyroidism was the only comorbidity that was
evaluated as an independent predictive factor for overall survival (OS) (HR 0.59, P = 0.02) and EC-specific survival
(HR 0.62, P = 0.05), but this association was seen only in the non-surgical patients. No other medications were found
to have a significant impact for OS, EC-specific survival or non-EC specific survival in multivariable analysis.
Conclusions: Our data indicate that certain comorbidities rather than medication use affect EC-specific survival or
non EC-specific survival in EC patients treated with CRT with or without surgery. Comorbidity information may
better guide individual treatment in EC.
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Concurrent chemoradiotherapy (CRT) followed by surgery
is widely accepted as the standard treatment for locally ad-
vanced esophageal carcinoma (EC). However, there is still
a portion of patients being excluded from this curative
combined therapy mainly because of the poor perform-
ance status due to comorbidities [1]. Until now, how these
common comorbidities influence EC patient survival is
known to a limited degree. In a retrospective study of a
large Esophagogastric Cancer Registry, postoperative* Correspondence: SHLin@mdanderson.org
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unless otherwise stated.mortality was found to increase in patients of advanced
age and with greater comorbidity [2]. By contrast, another
report recently revealed that there was no increased risk
for mortality in EC patients with diabetes or other com-
mon comorbidities selected for surgery [3]. So far, the lim-
ited prior studies focused mainly on EC patients treated
with surgery and with inconsistent results. Even less is
known on how these comorbidities affect clinical out-
comes for patients treated without surgery.
For patients with certain comorbidities, the medications
used for treating these ailments are inevitably used
throughout the treatment course. Recently, the importance
of the medication information has attracted more and more
attention. Firstly, a key advantage for analyzing medicationis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tient’s underlying health conditions than past medical his-
tory documentation. Second, the dose of the medications
may provide a better perspective on the severity of the co-
morbid condition. Third, the use of some medications has
already been reported to be associated with the risk and/or
therapy response of EC [4-6]. However the degree these
drugs affect prognosis of esophageal cancer is not known.
Furthermore, the relative impact that comorbid disease has
on prognosis as compared to the use of certain medications
for the specific ailments is also not well understood.
The purpose of our study was to understand the rela-
tive impact that comorbid diseases and medication use
have on the patients’ survival. We evaluated how these
two factors influenced EC-specific death and non EC-
specific death in a large cohort of EC patients treated
with CRT with or without surgery.
Methods
Patient selection
All patients had histologically proven primary esopha-
geal carcinoma and treated with concurrent CRT with
or without esophagectomy. A total of 1174 patients (560
and 614 patients with and without esophagectomy, re-
spectively) treated in our institution from January 1998
to April 2012 were included for this analysis. This study
was approved by the institutional review board of The
University of Texas MD Anderson Cancer Center and
was performed in accordance with the Declaration of
Helsinki [7].
Evaluations and interventions
Staging and restaging was done according to the 6th
(2002) edition of the American Joint Committee on
Cancer (AJCC) staging manual for esophageal carcinoma.
Patients were treated with concurrent CRT with or with-
out induction chemotherapy and following esophagec-
tomy. Radiation was delivered with 3-dimensional
conformal radiation (3D-CRT), intensity-modulated radi-
ation (IMRT), or proton beam therapy. The typical radi-
ation dose was 50.4 Gy in 28 fractions. All patients
received platin- or taxane-based chemotherapy with fluo-
rouracil. CRT response was evaluated according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
system at 0–3 months after the completion of CRT.
Esophagectomy was approved by the thoracic multidiscip-
linary group according the re-evaluation after CRT, and
was performed 4–8 weeks after CRT completion.
Data collection
Medical records were reviewed for baseline characteristics,
preexisting chronic comorbidities, preexisting regularly-
taken medications, treatment modalities, tumor control
and patients’ survival outcomes. According to the pastmedical history record, the preexisting chronic comorbidi-
ties including the following 4 most frequently occurring
groups: (1) hypertension; (2) cardiovascular disease (coron-
ary artery disease [CAD] and atrial fibrillation [AF] (any
types included, intermittent or persistent)); (3) pulmonary
disease (chronic obstructive pulmonary disease [COPD]
and asthma) and (4) metabolic diseases (diabetes and
hypothyroidism). Other medical comorbidities which in-
cluded less than 2.5% (30) of the patients were not included
in the analysis, such as cerebrovascular disease, gout,
hyperthyroidism, anemia and prostatic hypertrophy.
In total, 12 kinds of medications used for the above
comorbidities were also recorded: (1) anti-hypertensive
drugs (angiotensin-converting enzyme inhibitor/angio-
tensin receptor blockers (ACEi/ARB), beta-blocker, cal-
cium channel antagonist, alpha-1-adrenoceptor blocker
and diuretic) (2) cardiovascular drugs (cardiac glycoside
and coronary vasodilator), (3) bronchodilators, (4)
hypoglycemic agents (insulin, sulfonylureas, biguanide)
and (5) levothyroxine. Other antiarrhythmic drugs ex-
cept beta-blocker and cardiac glycoside, and other
hypoglycemic drugs were not included because the fre-
quency was less than 2.5% of the patients.
In addition, 6 kinds of other medications, frequently used
by this cohort of the patients, were also included: (1) ant-
acids, (2) non-steroidal anti-inflammatory drugs (NSAIDs),
(3) antihyperlipidemics (statins and other lipid-regulating
agents), (4) antithrombotics and (5) antidepressants. Since
all the patients recorded as having hypothyroidism also
regularly took levothyroxine, hypothyroidism/levothyroxine
was considered one variable in analysis.
Outcome definition
Local/regional failure was defined as the persistence or
recurrence of the primary tumor and regional lymph
nodes, while distant failure was defined as metastasis to
any site beyond the primary tumor and regional lymph
nodes. OS, EC-specific survival and non EC-specific sur-
vival were defined as the time from the end of CRT to
any cause of death, either due to esophageal carcinoma
or any cause of death other than esophageal carcinoma,
respectively. Since the date record of CRT end is missing
for one patient treated in 1998, leaving 1173 patients for
survival analysis.
Statistical analysis
The distribution of each categorical variable was sum-
marized in terms of its frequencies and percentages.
Fisher’s exact texts were used to assess measures of asso-
ciation in frequency tables. Survival curves were ob-
tained with the Kaplan-Meier method and compared
with log-rank tests. The Cox proportional hazards re-
gression model was used to evaluate the ability of patient
prognostic variables or surgery effect to predict survival.
Table 1 Patient and tumor characteristics
Characteristics Value or No. of patients (%)
Age at diagnosis (years)
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prognostic factor for loco-regional EC and it is expected
that the prognostic factors would have different impacts
on survival between surgery patients and non-surgery
patients, the interaction term of each prognostic factor
and surgery is included for each variable in the univari-
able analysis. The variables with either potentially signifi-
cant main effect or the interaction term (P < 0.10) were
selected and included in the multivariable mode for OS,
EC-specific survival and non EC-specific survival. A P
value less than 0.05 was considered statistically signifi-
cant in multivariable analysis. For each significant inter-
action term in the multivariate model, it indicates that
the corresponding variable affect survival differently in
surgery and non-surgery patient. Hence, the hazard rate
(HR) for death, 95% confidence interval [CI] and P value
of the variable were further calculated for surgery and
non-surgery patients respectively. All computations were
carried out in SAS version 9.3. (SAS Institute, Cary, NC)
and all statistical tests were 2-sided.Heavy alcohol use history 250(21.3)








Patient characteristics, comorbidities and medications
Baseline characteristics of the 1174 EC patients in our
cohort are listed in Table 1. The frequencies of the major
comorbidities and medications are presented in Table 2.
The most prevalent comorbidity was hypertension,
followed by diabetes, CAD, hypothyroidism, COPD and
asthma. Antacid, NSAIDS, statins, ACEi/ARB and beta-


















KPS: Karnofsky performance scores; BMI: body mass index; ADE:
adenocarcinoma; SCC: squamous cell carcinoma; 3DCRT: 3-dimensional
conformal radiation; IMRT: intensity-modulated radiation.Impact of comorbidities and medications on outcomes
The median follow-up for the whole cohort was 25 months
(3 to 186 months) with a 5y-OS of 38%. Besides the comor-
bidities and medications, the impact value of age, sex, race,
body mass index (BMI), heavy alcohol use history, smoke at
diagnosis, second malignancy, Karnofsky performance
scores, tumor histology, tumor location, tumor differenti-
ation, clinical stage, induction chemotherapy, radiation mo-
dality and their interactions with surgery were all tested in
univariate analysis. Other factors which showed a significant
impact on OS, EC-specific survival or non-EC specific sur-
vival in univariate analysis were listed in the footnote of
Table 2. All the parameters included in the multivariate ana-
lysis were listed in the footnote of Table 3. After adjusting
for patients’ baseline characteristics, AF was the only comor-
bidity that showed a significant impact on non-EC specific
survival in both univariable (Table 2, Figure 1) and multivar-
iable analysis (Table 3). For OS and EC-specific survival,
hypothyroidism/levothyroxine was also the only significant
factor in both univariable and multivariable analysis, with a
significant interaction with surgery. It had a significant im-
pact on OS (HR 0.59, 95% CI 0.38–0.93, P = 0.02) and EC-
Table 2 Univariate survival analysis of comorbidities, medications and their interactions with surgery
Overall survival EC-specific survival Non-EC specific survival
Variables No. (%) HR(95% CI)1 P1 HR(95% CI)1 P1 HR(95% CI)1 P1
Hypertension 620(52.8) 0.92(0.76-1.11) 0.38 0.92(0.73-1.16) 0.47 0.91(0.66-1.26) 0.57
Interaction with surgery 1.18(0.88-1.60) 0.27 1.00(0.69-1.45) 1.00 1.67(0.99-2.81) 0.05
CAD 184(15.7) 1.00(0.80-1.25) 0.99 0.88(0.66-1.16) 0.36 1.26(0.86-1.84) 0.24
Interaction with surgery 1.05(0.67-1.66) 0.83 0.94(0.51-1.70) 0.83 1.29(0.63-2.64) 0.49
AF 63(5.4) 1.23(0.89-1.71) 0.22 0.84(0.53-1.34) 0.48 2.19(1.36-3.51) <0.01
Interaction with surgery 0.63(0.28-1.44) 0.28 0.57(0.17-1.95) 0.37 0.68(0.22-2.05) 0.49
COPD 65(5.5) 1.14(0.80-1.62) 0.47 0.69(0.40-1.18) 0.17 2.22(1.37-3.59) <0.01
Interaction with surgery 0.66(0.29-1.52) 0.33 0.66(0.19-2.31) 0.51 0.68(0.22-2.08) 0.50
Asthma 36(3.1) 1.09(0.68-1.75) 0.71 0.79(0.41-1.53) 0.48 1.81(0.92-3.56) 0.09
Interaction with surgery 1.38(0.59-3.22) 0.46 1.80(0.59-5.46) 0.30 0.93(0.25-3.56) 0.92
Diabetes 193(16.4) 1.10(0.87-1.40) 0.43 1.13(0.85-1.51) 0.39 1.04(0.68-1.61) 0.84
Interaction with surgery 0.98(0.64-1.50) 0.92 0.72(0.42-1.26) 0.25 1.59(0.81-3.15) 0.18
Hypothyroidism/levothyroxine 102(8.7) 0.59(0.42-0.83) <0.01 0.52(0.33-0.80) <0.01 0.74(0.43-1.29) 0.29
Interaction with surgery 2.26(1.32-3.86) <0.01 2.27(1.14-4.52) 0.02 2.21(0.94-5.21) 0.07
ACEi/ARB 350(29.8) 0.99(0.81-1.21) 0.95 0.94(0.73-1.20) 0.60 1.10(0.78-1.56) 0.58
Interaction with surgery 1.06(0.76-1.47) 0.72 0.97(0.64-1.46) 0.87 1.28(0.74-2.22) 0.38
beta-Blocker 217(18.5) 0.95(0.76-1.18) 0.65 1.05(0.81-1.36) 0.73 0.74(0.49-1.12) 0.16
Interaction with surgery 1.07(0.71-1.61) 0.73 0.71(0.42-1.21) 0.21 2.29(1.18-4.43) 0.01
Calcium antagonist 172(14.7) 1.01(0.79-1.30) 0.92 1.05(0.78-1.42) 0.73 0.94(0.60-1.48) 0.79
Interaction with surgery 1.24(0.82-1.86) 0.31 1.06(0.63-1.77) 0.82 1.63(0.82-3.23) 0.16
alpha-1-Adrenoceptor blocker 105(8.9) 1.19(0.90-1.58) 0.23 1.08(0.76-1.55) 0.67 1.45(0.90-2.32) 0.12
Interaction with surgery 1.12(0.67-1.87) 0.66 1.05(0.54-2.04) 0.89 1.20(0.54-2.70) 0.65
Diuretic 200(17.0) 1.01(0.80-1.26) 0.96 0.93(0.7-1.24) 0.63 1.13(0.77-1.66) 0.53
Interaction with surgery 1.18(0.79-1.77) 0.42 1.27(0.77-2.08) 0.35 1.07(0.53-2.16) 0.85
Cardiac glycoside 48(4.1) 1.04(0.72-1.51) 0.83 0.67(0.38-1.17) 0.16 1.83(1.11-3.04) 0.02
Interaction with surgery 2.09(0.94-4.62) 0.07 2.41(0.77-7.51) 0.13 1.82(0.59-5.60) 0.30
Coronary vasodilator 33(2.8) 0.61(0.36-1.04) 0.07 0.67(0.35-1.25) 0.21 0.50(0.19-1.36) 0.18
Interaction with surgery 1.66(0.66-4.15) 0.28 0.69(0.15-3.18) 0.63 3.89(1.02-14.88) 0.05
Bronchodilator 33(2.8) 1.34(0.84-2.15) 0.22 0.53(0.22-1.27) 0.15 3.35(1.89-5.93) <0.01
Interaction with surgery 0.73(0.27-1.98) 0.53 2.05(0.54-7.74) 0.29 0.21(0.03-1.62) 0.13
Insulin 37(3.2) 0.81(0.47-1.37) 0.43 0.66(0.32-1.32) 0.24 1.17(0.52-2.65) 0.71
Interaction with surgery 1.87(0.67-5.25) 0.23 1.27(0.27-6.07) 0.76 2.76(0.67-11.31) 0.16
Sulfonylurea 75(6.4) 1.34(0.95-1.88) 0.09 1.53(1.04-2.26) 0.03 0.94(0.46-1.93) 0.87
Interaction with surgery 0.71(0.37-1.37) 0.31 0.35(0.13-0.92) 0.03 2.02(0.73-5.59) 0.18
Biguanide 104(8.9) 0.99(0.70-1.40) 0.97 1.11(0.75-1.65) 0.60 0.74(0.36-1.51) 0.41
Interaction with surgery 0.85(0.48-1.49) 0.57 0.62(0.31-1.26) 0.19 1.62(0.60-4.35) 0.34
Antacid 657(56.0) 0.74(0.62-0.89) <0.01 0.79(0.63-0.99) 0.04 0.67(0.48-0.92) 0.01
Interaction with surgery 1.25(0.92-1.69) 0.15 1.21(0.84-1.76) 0.31 1.30(0.77-2.19) 0.30
NSAIDs 507(43.2) 1.10(0.92-1.33) 0.30 1.06(0.84-1.33) 0.63 1.19(0.86-1.64) 0.30
Interaction with surgery 0.90(0.66-1.22) 0.50 0.89(0.61-1.29) 0.54 0.94(0.55-1.6) 0.82
Statins 400(34.1) 0.84(0.69-1.02) 0.08 0.81(0.64-1.04) 0.09 0.87(0.62-1.23) 0.43
Interaction with surgery 1.19(0.86-1.64) 0.30 1.05(0.70-1.56) 0.81 1.53(0.89-2.66) 0.13
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Table 2 Univariate survival analysis of comorbidities, medications and their interactions with surgery (Continued)
Variables NO. (%) HR(95%CI)1 P1 HR(95%CI)1 P1 HR(95%CI)1 P1
Other lipid-regulating agents 60(5.1) 0.88(0.55-1.41) 0.60 1.08(0.64-1.82) 0.77 0.46(0.15-1.45) 0.19
Interaction with surgery 0.75(0.36-1.56) 0.45 0.41(0.16-1.07) 0.07 2.53(0.64-10.06) 0.19
Antithrombotic 119(10.1) 0.99(0.75-1.30) 0.94 0.86(0.61-1.22) 0.40 1.29(0.83-2.00) 0.25
Interaction with surgery 1.03(0.59-1.80) 0.93 0.91(0.43-1.93) 0.80 1.19(0.51-2.78) 0.68
Antidepressant 215(18.3) 0.99(0.79-1.24) 0.92 0.98(0.74-1.30) 0.91 1.01(0.67-1.50) 0.97
Interaction with surgery 1.06(0.72-1.57) 0.76 0.89(0.55-1.47) 0.66 1.43(0.75-2.73) 0.27
1Other factors analyzed in univariate analysis include: age, sex, race, BMI, heavy alcohol use history, smoking at diagnosis, second malignancy, Karnofsky
performance scores, tumor histology, tumor location, tumor differentiation, clinical stage, induction chemotherapy, radiation modality and their interactions
with surgery.
EC: esophageal carcinoma; HR: hazard rate; CI: confidence interval; CAD: coronary artery disease; AF: atrial fibrillation; COPD: chronic obstructive pulmonary
disease; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; NSAIDs: non-steroidal anti-inflammatory drugs.
Table 3 Multivariate survival analysis of comorbidities, medications and their interactions with surgery
Overall survival EC-specific survival Non-EC specific survival
Variables HR(95% CI)1 P1 HR(95% CI)2 P2 HR(95% CI)3 P3
Hypertension - - - - 0.94(0.66-1.33) 0.71
Interaction with surgery - - - - 1.36(0.77-2.41) 0.29
AF - - - - 1.72(1.07-2.77) 0.03
Interaction with surgery - - - - - -
COPD - - - - 1.43(0.88-2.38) 0.15
Interaction with surgery - - - - - -
Asthma - - - - 1.42(0.75-2.70) 0.28
Interaction with surgery - - - - - -
Hypothyroidism/ levothyroxine 0.59(0.38-0.93) 0.02 0.62(0.38-1.01) 0.05 0.78(0.44-1.37) 0.39
Interaction with surgery 2.04(1.09-3.83) 0.03 2.20(1.03-4.69) 0.04 1.50(0.61-3.69) 0.38
beta-Blocker - - - - 0.70(0.45-1.07) 0.10
Interaction with surgery - - - - 2.26(1.09-4.68) 0.03
Cardiac glycoside 1.50(0.92-2.44) 0.10 - - 1.31(0.78-2.20) 0.30
Interaction with surgery 1.19(0.48-2.96) 0.71 - - - -
Coronary vasodilator 0.93(0.54-1.61) 0.80 - - 0.45(0.16-1.28) 0.13
Interaction with surgery - - - - 2.92(0.72-11.97) 0.13
Bronchodilator - - - - 1.89(0.98-3.62) 0.06
Interaction with surgery - - - - - -
Sulfonylurea 1.15(0.81-1.65) 0.43 1.28(0.79-2.07) 0.32 - -
Interaction with surgery - - 0.49(0.18-1.36) 0.17 - -
Antacid 0.94(0.79-1.12) 0.47 0.92(0.75-1.13) 0.41 0.80(0.61-1.05) 0.11
Interaction with surgery - - - - - -
Statin 0.92(0.76-1.11) 0.38 0.87(0.70-1.07) 0.19 - -
Interaction with surgery - - - - - -
Other lipid-regulating agents - - 0.98(0.56-1.71) 0.94 - -
Interaction with surgery - - 0.66(0.24-1.77) 0.40 - -
1Adjusted for the interactions of age, race, tumor histology and tumor location with surgery, BMI, smoking at diagnosis, Karnofsky performance scores, tumor
location, clinical stage, radiation modality and surgery for overall survival.
2Adjusted for the interactions of race, age, tumor histology and tumor location with surgery, sex, race, age, smoking at diagnosis, tumor histology, tumor length,
tumor differentiation, clinical stage, radiation modality and surgery for EC-specific death free survival.
3Adjusted for the interactions of tumor histology and tumor location with surgery, age, Karnofsky performance scores, tumor histology, induction chemotherapy,
radiation modality and surgery for non-EC specific death free survival.
EC: esophageal carcinoma; HR: hazard rate; CI: confidence interval; AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease.
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Figure 1 Non-esophageal carcinoma specific survival for
patients with and without atrial fibrillation.
He et al. BMC Cancer  (2015) 15:111 Page 6 of 10specific survival (HR 0.62, 95% CI 0.38–1.01, P = 0.05) for
non-surgery patients but not for the surgery patients.
To better interpret the significant interaction of
hypothyroidism/levothyroxine and surgery for OS and
EC-specific survival, the survival curves stratified by
hypothyroidism/levothyroxine and surgery were further
presented in Figure 2A and B. The 5 year OS (45% vs.
25%, P = 0.003) and EC-specific survival (62% vs. 38%, P =
0.004) for patients with hypothyroidism/levothyroxine was
significant higher than those without hypothyroidism/
levothyroxine for non-surgery patients but not for surgery
patients (P > 0.05).Characteristics difference between patients with/without
AF and hypothyroidism/levothyroxine
Since AF and hypothyroidism/levothyroxine were found to
significantly impact patients’ survival, we compared the dif-
ference of the clinico-pathologic characteristics between pa-
tients with and without AF (Table 4) and hypothyroidism/Figure 2 Survival stratified by hypothyroidism and surgery status for
B: Esophageal carcinoma-specific survival.levothyroxine (Table 5), respectively. There were more pa-
tients who are older than 64 yrs (P < 0.01), had no surgery
(P < 0.01), treated with IMRT/proton therapy (P < 0.01),
without a complete CRT response (P = 0.02) and had a
lower distant failure rate (P = 0.01) in the AF group than in
non-AF group. No difference was observed on other clinico-
pathologic characteristics between the two groups (Table 4).
There were more patients who are female (P < 0.01),
without smoke at diagnosis (P < 0.01), with squamous
cell carcinoma (SCC) histology (P = 0.05) and earlier
clinical stage (P = 0.02) in the hypothyroidism/levothyr-
oxine group than in non-hypothyroidism/levothyroxine
group. No difference was observed on other clinico-
pathologic characteristics between the two groups
(Table 5).Discussion
In our retrospective study, by simultaneously analyzing
the impact value of 7 kinds of frequently occurring co-
morbidities and 18 types of regularly-taken medications
on EC patient survival, we identified that certain comor-
bidities (hypothyroidism and AF) but not specific medi-
cations that affected EC-specific survival or non-EC
specific survival in a large EC cohort treated with CRT
with or without surgery.
It is generally recognized that comorbidities may affect
patients’ prognosis mainly by impacting the non-cancer
specific survival [1]. In addition, patients with comorbid-
ities are more likely to experience severe treatment tox-
icities and even treatment related death [8]. For
example, AF, which remains one of the most frequent
complications after esophagectomy, has been reported
to be associated with the pre-existing AF and increased
postoperative mortality by several studies [9,10]. In our
study, we found that AF was an adverse prognosticpatients with esophageal carcinoma. A: Overall survival,
Table 4 Characteristics of esophageal carcinoma patients with or without Atrial fibrillation
Atrial fibrillation P1
Variables No Yes
Sex Female 174(15.7%) 8(12.7%) 0.72
Male 937(84.3%) 55(87.3%)
Race non-White 143(12.9%) 3(4.8%) 0.07
White 968(87.1%) 60(95.2%)
BMI ≤25 271(29.1%) 14(24.1%) 0.45
>25 660(70.9%) 44(75.9%)
Age (years) ≤64 601(54.1%) 12(19%) <0.01
>64 510(45.9%) 51(81%)
Heavy alcohol use history No 868(78.3%) 54(85.7%) 0.21
Yes 241(21.7%) 9(14.3%)
Smoke at diagnosis No 869(78.5%) 53(84.1%) 0.34
Yes 238(21.5%) 10(15.9%)
KPS ≤70 107(9.6%) 10(15.9%) 0.13
>70 1004(90.4%) 53(84.1%)
Tumor histology ADC 864(79.2%) 50(79.4%) 1.00
SCC 227(20.8%) 13(20.6%)
Tumor location Upper/middle 152(13.7%) 7(11.1%) 0.71
Low 959(86.3%) 56(88.9%)
Tumor differentiation Well/moderate 487(44.4%) 30(47.6%) 0.70
Poor 611(55.6%) 33(52.4%)
Tumor length (cm) ≤5 564(57.7%) 35(59.3%) 0.89
>5 414(42.3%) 24(40.7%)
Clinical stage I-II 403(37.2%) 28(44.4%) 0.28
III-IV 680(62.8%) 35(55.6%)
Surgery No 567(51%) 47(74.6%) <0.01
Yes 544(49%) 16(25.4%)
Radiation modality 3DCRT 456(41%) 13(20.6%) <0.01
IMRT/proton 655(59%) 50(79.4%)
Induction chemotherapy No 662(59.6%) 44(69.8%) 0.11
Yes 449(40.4%) 19(30.2%)
CRT complete response No 658(62.3%) 47(77%) 0.02
Yes 399(37.7%) 14(23%)
Chemotherapy after relapse No 948 (85.3%) 56 (88.9%) 0.58
Yes 163 (14.7%) 7 (11.1%)
Local/regional failure rate No 298(30.5%) 17(33.3%) 0.64
Yes 678(69.5%) 34(66.7%)
Distant failure rate No 556(54.9%) 38(73.1%) 0.01
Yes 456(45.1%) 14(26.9%)
1Fisher exact test.
KPS: Karnofsky performance scores; BMI: body mass index; ADC: adenocarcinoma; SCC: squamous cell carcinoma; 3DCRT: 3-dimensional conformal radiation; IMRT:
intensity-modulated radiation: CRT: chemoradiotherapy.
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patients regardless of whether they received surgery or
not. Considering the significant impact of AF on theprognosis of EC, an improved management of pre-
existing AF in EC patients before and during cancer
treatments should be recommended.
Table 5 Characteristics of esophageal carcinoma patients with or without hypothyroidism/levothyroxine
Hypothyroidism/Levothyroxine P1
Variables No Yes
Sex Female 148(13.8%) 34(33.3%) <0.01
Male 924(86.2%) 68(66.7%)
Race non-White 131(12.2%) 15(14.7%) 0.44
White 941(87.8%) 87(85.3%)
BMI ≤25 262(29.1%) 23(25.8%) 0.62
>25 638(70.9%) 66(74.2%)
Age (years) ≤64 569(53.1%) 44(43.1%) 0.06
>64 503(46.9%) 58(56.9%)
Heavy alcohol use history No 839(78.4%) 83(81.4%) 0.53
Yes 231(21.6%) 19(18.6%)
Smoke at diagnosis No 830(77.6%) 92(91.1%) <0.01
Yes 239(22.4%) 9(8.9%)
KPS ≤70 104(9.7%) 13(12.7%) 0.30
>70 968(90.3%) 89(87.3%)
AF No 1013(94.5%) 98(96.1%) 0.65
Yes 59(5.5%) 4(3.9%)
Tumor histology ADC 841(79.9%) 73(71.6%) 0.05
SCC 211(20.1%) 29(28.4%)
Tumor location Upper/middle 140(13.1%) 19(18.6%) 0.13
Low 932(86.9%) 83(81.4%)
Tumor differentiation Well/moderate 477(45.0%) 40(39.6%) 0.35
Poor 583(55.0%) 61(60.4%)
Tumor length (cm) ≤5 537(56.9%) 62(66.7%) 0.08
>5 407(43.1%) 31(33.3%)
Clinical stage I-II 383(36.6%) 48(48.5%) 0.02
III-IV 664(63.4%) 51(51.5%)
Surgery No 553(51.6%) 64(59.8%) 0.12
Yes 519(48.4%) 41(40.2%)
Radiation modality 3DCRT 430(40.1%) 39(38.2%) 0.75
IMRT/proton 642(59.9%) 63(61.8%)
Induction chemotherapy No 638(59.5%) 68(66.7%) 0.17
Yes 434(40.5%) 34(33.3%)
CRT complete response No 651(63.5%) 54(58.1%) 0.31
Yes 374(36.5%) 39(41.9%)
Chemotherapy after relapse No 914(85.3%) 90(88.2%) 0.47
Yes 158(14.7%) 12(11.8%)
Local/regional failure rate No 290(31.0%) 25(26.9%) 0.48
Yes 644(69.0%) 68(73.1%)
Distant failure rate No 532(55.0%) 62(64.6%) 0.08
Yes 436(45.0%) 34(35.4%)
1Fisher exact test.
KPS: Karnofsky performance scores; BMI: body mass index; ADC: adenocarcinoma; SCC: squamous cell carcinoma; AF: atrial fibrillation; 3DCRT: 3-dimensional con-
formal radiation; IMRT: intensity-modulated radiation: CRT: chemoradiotherapy.
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protective factor for OS in non-surgical patients, possibly
by affecting EC-specific death, since it showed no impact
on non-EC specific survival in our analysis. Although the
impact of hypothyroidism and human cancer has been a
controversial issue [11,12], some recent data suggests that it
is associated with a good prognosis of certain human can-
cers (head and neck, lung and renal cancers) [12-14]. Our
study is the first to make this association for EC. We also
found that patients with hypothyroidism tended to have
earlier clinical stage disease than euthyroid patients, which
was also observed for breast cancer patients [15]. The
underlying mechanisms that have been proposed for the
role of hypothyroidism in cancer are mainly through inter-
fering the process of cell proliferation and apoptosis, since
hypothyroidism is characterized by reduced production of
thyroid hormone [16]. In animal models, thyroid hormone
can stimulate tumor growth and metastasis, whereas
hypothyroidism shows the opposite effects [17,18]. While
to date, there is no specific study determining the mechan-
ism by which hypothyroidism affect the prognosis of EC. It
is unclear why the survival benefit of hypothyroidism was
not seen for surgical patients. This observation will need
confirmation in future studies.
There have been a number of reports showing that cer-
tain medications have an impact on EC. Biguanide (met-
formin), statins and NSAIDs (aspirin) have been reported
to be associated with a clinically reduced EC incidence
[6,19] and have an anti-tumor effect in EC cells [20-22].
Recently, a retrospective study showed that metformin use
is associated with an increased CRT response in esopha-
geal adenocarcinoma, but no benefit of metformin was ob-
served for OS [4]. In our analysis, we could not identify a
single medication effect on patient survival in EC.
Although the survival benefit of certain drugs has been re-
ported in some other human cancers [23,24], the recog-
nized heterogeneity among the various studies [25] and
the survival influence of certain drugs could be cancer-
specific. To date, there are not reports that support the
survival influence of any medications on EC patients.
The limitations of our study relate to the retrospective
collection of comorbid information from the medical re-
cords elicited from physicians’ clinical evaluations, which
may underestimate the existence of certain comorbidities if
they were not asked or were not willingly provided by the
patients. Second, it is important to note that the prevalence
of certain comorbidities and medications can affect the
statistical power to detect their impact on patient survival.
Thus, the lack of the statistical significance for a certain
variable with low prevalence should be interpreted with
caution. Third, although our data does corroborate previ-
ously published studies supporting the protective role of
hypothyroidism in certain types of human cancers, we can’t
exclude the influence of levothyroxine on EC prognosis inour study, as all the patients with hypothyroidism also took
levothyroxine. In addition, there is also a possibility that pa-
tients may take levothyroxine due to reasons other than
hypothyroidism. Further studies are needed to better clarify
the roles of hypothyroidism and levothyroxine on EC prog-
nosis in different cohort of EC patients.
Conclusion
In conclusion, despite the growing evidence that some
medications and/or their underlying comorbidities predict
patients’ prognosis in some human cancers, certain comor-
bidities (hypothyroidism and AF) rather than commonly-
used medications affect patient survival in EC patients
treated with CRT with or without surgery. Comorbidity in-
formation should be taken into consideration when individ-
ualized treatment decisions are made for EC patients.
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